ArticleJournal of fish diseases2025
Controlled Field Trial of Pancreas Disease Vaccines in Farmed Atlantic Salmon: Effects on Growth and Mortality During a SAV2 Outbreak.
Article in Journal of fish diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Vaccination Reduces Shedding of Salmonid Alphavirus Subtype 3, but Bacterial Co-Infection Influences the Effect.Journal of fish diseases · 2026Article
- Plasmid-DNA EncodedPharmaceutics · 2026Article
- DNA Vaccination in Farmed Fish with a Focus on Salmonid Alphavirus Infection in Atlantic Salmon (Viruses · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreas disease (PD), caused by salmonid alphavirus (SAV), is a concern for salmon aquaculture in Scotland, Ireland and Norway. This article presents results from a controlled field trial monitoring three study groups from vaccination to harvest. The groups represented a subset of the total fish population within a single sea cage, reared under commercial farming conditions. The trial aimed to evaluate the effects of two licensed PD vaccines in Norway-ALPHA JECT micro 1 PD (AJm1PD) and Clynav-on growth and mortality during a PD outbreak, relative to an unvaccinated control group. Clinical PD, caused by SAV subtype 2, was confirmed in June 2024, approximately 14 months after sea transfer and 2 months before harvest. At harvest, both vaccinated groups exhibited significantly higher weights compared to the control group, with mean increases of 0.19 kg (95% CI: 0.05-0.33) for AJm1PD and 0.38 kg (95% CI: 0.24-0.51) for Clynav. Significant risk differences (%) in mortality were observed between the PD-vaccinated groups and the control during the outbreak, with lower mortality in vaccinated fish (AJm1PD: -0.60 [95% CI: -0.98 to -0.22]; Clynav: -1.10 [95% CI: -1.45 to -0.74]). To account for potential misclassification of mortalities, bias-adjusted estimates were calculated, revealing greater risk differences compared to unadjusted estimates (AJm1PD: -0.99 [95% CI: -1.53 to -0.45]; Clynav: -2.07 [95% CI: -2.58 to -1.56]). These findings suggest that failing to adjust for misclassification biases the results toward the null, leading to an underestimation of the true effect size. In contrast, risk ratios remained largely unaffected by these adjustments. Overall, the study suggests that both vaccines improved outcomes, with the DNA vaccine (Clynav) showing a more pronounced effect on both growth and survival compared to the inactivated SAV vaccine (AJm1PD), while also highlighting methodological challenges in conducting controlled field trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.